Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Drug Design

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_1735-3

Synonyms

Definition

The process of discovering, inventing, improving, and/or testing a new therapeutic agent for the treatment of a specific disease.

Characteristics

Most of the drugs used in classical cancer chemotherapy were discovered by serendipity or by trial and error. A problem with such drugs arises because, in addition to having a desirable cytotoxic effect on cancer cells, many of these drugs can adversely affect rapidly dividing normal cells, such as gastric mucosal cells lining the stomach or hematopoietic stem cells in the bone marrow. This lack of specificity is a major contributing factor for the severity of side effects of classical cancer chemotherapy, which can include immunosuppression, nausea, vomiting and other gastrointestinal toxicities, and damage to the brain (neurotoxicity), heart (cardiotoxicity), liver (hepatotoxicity), kidney (renal toxicity), and lungs (pulmonary toxicity). The recent trend in anticancer drug...

Keywords

Chronic Myeloid Leukemia Maximum Tolerable Dose Quantitative Structure Activity Relationship Chronic Myelogenous Leukemia Good Manufacture Practice 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access

References

  1. Faivre S, Djelloul S, Raymond E (2006) New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 33(4):407–420CrossRefPubMedGoogle Scholar
  2. Lord CJ, Ashworth A (2010) Biology-driven cancer drug development: back to the future. BMC Biol 8:38CrossRefPubMedPubMedCentralGoogle Scholar
  3. Rowinsky EK (2003) Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies. Clin Oncol 21(10 Suppl):175s–186sCrossRefGoogle Scholar

See Also

  1. (2012) Bioinformatics. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, pp 403–404. doi: 10.1007/978-3-642-16483-5_631Google Scholar
  2. (2012) Biologically effective dose. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 404. doi: 10.1007/978-3-642-16483-5_638Google Scholar
  3. (2012) Biomarkers. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, pp 408–409. doi: 10.1007/978-3-642-16483-5_6601Google Scholar
  4. (2012) Chemoresistance. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 790. doi: 10.1007/978-3-642-16483-5_1076Google Scholar
  5. (2012) Dasatinib. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 1060. doi: 10.1007/978-3-642-16483-5_1518Google Scholar
  6. (2012) Humanized monoclonal antibody. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 1760. doi: 10.1007/978-3-642-16483-5_6844Google Scholar
  7. (2012) Maximum tolerable dose. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 2188. doi: 10.1007/978-3-642-16483-5_3566Google Scholar
  8. (2012) Monoclonal antibody therapy. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, pp 2367–2368. doi: 10.1007/978-3-642-16483-5_3823Google Scholar
  9. (2012) Personalized medicine. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 2828. doi: 10.1007/978-3-642-16483-5_4476Google Scholar
  10. (2012) Pharmacodynamics. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 2840. doi: 10.1007/978-3-642-16483-5_4495Google Scholar
  11. (2012) Pharmacokinetics. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 2845. doi: 10.1007/978-3-642-16483-5_4500Google Scholar
  12. (2012) Philadelphia chromosome. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 2864. doi: 10.1007/978-3-642-16483-5_4520Google Scholar
  13. (2012) Systems biology. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 3598. doi: 10.1007/978-3-642-16483-5_5643Google Scholar
  14. (2012) Tyrosine kinase. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 3822. doi: 10.1007/978-3-642-16483-5_6079Google Scholar
  15. (2012) Xenograft. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 3967. doi: 10.1007/978-3-642-16483-5_6278Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Pharmacology and ToxicologyUniversity of Mississippi Medical CenterJacksonUSA